AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15330403
Drug: Psychosocial service
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial service utilization (therapy with a psychologist, self-help group, therapy with a social worker, therapy with another type of provider)
Trial: 15330403
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of alcohol/drug abuse disorders
Trial: 11130743
Drug: Sildenafil 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 200 mg
Trial: 9228814
Drug: Ineraid cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineraid cochlear implant with analog processing
Trial: 9228814
Drug: Nucleus cochlear
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus cochlear implant with feature-extraction processing
Trial: 9228814
Drug: Both Ineraid
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Ineraid and Nucleus cochlear implants
Trial: 8112068
Drug: Locobase (moisturizer)
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locobase (moisturizer) used for 2 weeks (period L)
Trial: 8112068
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (period C)
Trial: 23913601
Drug: Selective infarct-related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective infarct-related artery (sIRA) infusion of tirofiban (10 g/kg body weight) through aspiration catheter followed by 12 hours of intravenous infusion (0.1 g/kg/min)
Trial: 23913601
Drug: Conventional intracoronary
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intracoronary (IC) administration of tirofiban (10 g/kg body weight) through guiding catheter followed by 12 hours of intravenous infusion (0.1 g/kg/min)
Trial: 23913601
Drug: sIRA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sIRA infusion of tirofiban
Trial: 23913601
Drug: Conventional IC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional IC administration of tirofiban
Trial: 18436152
Drug: IV/IA (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV/IA (0.6 mg/kg IV ≤ 60 mg, followed by 0.3 mg/kg IA ≤ 30 mg)
Trial: 18436152
Drug: IA therapy
RxNorm normalized name: A cd33/cd3 bispecific t-cell engager antibody for acute myeloid leukemia therapy
DrugBank: Eluvixtamab (DB17252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA therapy
Trial: 8713772
Drug: VIDAS D‐dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIDAS D‐dimer ELISA, cut-off level of 500 ng/ml
Trial: 30206824
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% finasteride combined with topical 3% minoxidil
Trial: 30206824
Drug: Topical 3%
RxNorm normalized name: sulfur topical 3% topical soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 3% minoxidil solution as monotherapy
Trial: 30371169
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise training with lipopolysaccharide 0.1 ng/mL
Trial: 30371169
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise training with lipopolysaccharide 1.0 ng/mL
Trial: 27423256
Drug: TAK-063 (PDE10A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 (PDE10A inhibitor)
Trial: 25483462
Drug: GC FLU
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC FLU Injection
Trial: 17613965
Drug: Gamma-hydroxybutyrate (GHB)
RxNorm normalized name: gamma-Hydroxybutyric acid
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-hydroxybutyrate (GHB) 50 mg/kg bodyweight, q.i.d.
Trial: 17613965
Drug: Diazepam 0.5
RxNorm normalized name: diazepam 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.5 mg/kg bodyweight, q.i.d.
Trial: 3182457
Drug: Ofloxacin 100
RxNorm normalized name: ofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 100 mg bd
Trial: 3182457
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg bd
Trial: 31194645
Drug: Traditional three-level
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional three-level drug distribution system
Trial: 26553733
Drug: Intralesional Mycobacterium
RxNorm normalized name: Mycobacterium phlei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Mycobacterium w (Mw) vaccine
Trial: 23954520
Drug: Intramuscular magnesium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular magnesium sulphate (IMMG)
Trial: 19565120
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl benzoate (BB2 group) - two applications of 12.5% BB over 24 hours
Trial: 19565120
Drug: Topical benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzyl benzoate (BB1 group) - single application of 12.5% BB over 24 hours
Trial: 19565120
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (IV group) - 150‐200 microg/kg
Trial: 11169174
Drug: Pulsed monochromatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed monochromatic infrared (956 nm) and red (637 nm) light therapy
Trial: 11169174
Drug: Standard ulcer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ulcer therapy (Control)
Trial: 793705
Drug: Antilymphocyte globulin
RxNorm normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antilymphocyte globulin (ALG) treatment, 20 mg/kg-d intravenously for 10 days after transplantation
Trial: 28375641
Drug: Curcumin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin and Boswellia serrata supplement
Trial: 12738463
Drug: Liquid sodium
RxNorm normalized name: SODIUM SALICYLATE 486 g in 1 L ORAL LIQUID [AquaPrime Liquid Sodium Salicylate]
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid sodium phosphate (45 ml at 7:00 PM, 45 ml 3 hours before colonoscopy)
Trial: 12738463
Drug: Tablet sodium
RxNorm normalized name: sodium fluoride Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet sodium phosphate (20 tablets at 7:00 PM, 20 tablets 3-5 hours before colonoscopy)
Trial: 12738463
Drug: Tablet sodium
RxNorm normalized name: sodium fluoride Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet sodium phosphate
Trial: 9061218
Drug: Azelastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine eye drops administered 30 min after ASCC
Trial: 9061218
Drug: Azelastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine eye drops after 7 days of treatment, 30 min after ASCC
Trial: 25846715
Drug: d-AMPH 5
RxNorm normalized name: 5-HYDROXYTRYPTOPHAN, D-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-AMPH 5 mg/70 kg
Trial: 25846715
Drug: d-AMPH 10
RxNorm normalized name: D & C YELLOW #10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-AMPH 10 mg/70 kg
Trial: 25846715
Drug: d-AMPH 20
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-AMPH 20 mg/70 kg
Trial: 21224436
Drug: Intravenous ω‐3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ω‐3 polyunsaturated fatty acids (PUFAs) administered as a single dose of a lipid emulsion containing 4.1 g of ω‐3 PUFAs during HD
Trial: 21224436
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) administered during HD
Trial: 10886487
Drug: On-demand beta2-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand beta2-agonist inhalation
Trial: 10886487
Drug: Regular beta2-agonist
RxNorm normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular beta2-agonist inhalation
Trial: 9311207
Drug: Acetated Ringer
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer solution containing 0.5 mmol.l‐1 of Mg2+ (Group II)
Trial: 9311207
Drug: Acetated Ringer
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer solution containing 1.0 mmol.l‐1 of Mg2+ (Group III)
Trial: 9311207
Drug: Acetated Ringer
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer solution containing 2.0 mmol.l‐1 of Mg2+ (Group IV)
Trial: 9311207
Drug: Acetated Ringer
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer solution containing 4.0 mmol.l‐1 of Mg2+ (Group V)
Trial: 9311207
Drug: Mg(2+)‐free acetated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg(2+)‐free acetated Ringer solution (Group I)
Trial: 8451670
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no beta-blockers)
Trial: 2951828
Drug: Combination fenoterol/ipratropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination fenoterol/ipratropium
Trial: 18550933
Drug: Candesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (angiotensin receptor blocker)
Trial: 12439649
Drug: 2512 kJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2512 kJ (600 kcal) daily energy deficit diet (ED)
Trial: 10338454
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin treatment (>/=24‐hour insulin‐glucose infusion followed by multidose subcutaneous insulin)
Trial: 10338454
Drug: Routine antidiabetic
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antidiabetic therapy (control group)
Trial: 10338454
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine antidiabetic therapy)
Trial: 1782080
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (two monthly cycles of intravenous doxorubicin/cyclophosphamide/5‐fluorouracil before locoregional therapy and four cycles subsequently)
Trial: 1782080
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (six monthly cycles following locoregional therapy)
Trial: 27817918
Drug: Krill oil
RxNorm normalized name: Krill oil
DrugBank: Krill oil (DB16615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krill oil (945 mg/day EPA + 510 mg/day DHA)
Trial: 27817918
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1000 mg/day EPA + 500 mg/day DHA)
Trial: 28295445
Drug: Placebo (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olive oil 1500 mg/day)
Trial: 27058408
Drug: Lung impedance
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung impedance (LI)‐guided treatment
Trial: 22676398
Drug: Internet-based aftercare
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based aftercare program (individualized self-monitoring module and weekly 90-min chat sessions)
Trial: 17416108
Drug: Ceftazidime 2
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2 x 3 g/24 hours
Trial: 17416108
Drug: Ceftazidime divided
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime divided into 6 administrations of 2 x 3 g/24 hours
Trial: 17416108
Drug: Modified dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified dosing regimen (1 g x 6 administrations)
Trial: 15021446
Drug: Raloxifene +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene + low-dose, transdermal estrogen (RLX+E)
Trial: 9552032
Drug: Simultaneous radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous radiotherapy plus chemotherapy (arm B)
Trial: 7925193
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg succimer/kg body wt
Trial: 7925193
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg succimer/kg body wt
Trial: 9678091
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Trial: 9678091
Drug: Monophasic oral
RxNorm normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Trial: 29142143
Drug: DHA 2
RxNorm normalized name: DHA 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA 2 g/day
Trial: 18377250
Drug: Cortical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks, targeted by functional imaging at approximately 50% of motor movement threshold.
Trial: 18377250
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rehabilitation therapy without CS) for 6 weeks.
Trial: 18377250
Drug: Cortical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks.
Trial: 16670135
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ramipril once daily for 24 weeks
Trial: 6337558
Drug: UV-B radiation
RxNorm normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV-B radiation (six daily treatments of one minimal erythemal dose (MErD) prior to starting daily applications of a 0.02% mechlorethamine ointment and thereafter one MErD weekly)
Trial: 6337558
Drug: Topical applications
RxNorm normalized name: honey based topical applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical applications of mechlorethamine (0.02% ointment) without UV-B
Trial: 29749323
Drug: δ-tocotrienol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: δ-tocotrienol (300 mg twice daily)
Trial: 24524367
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a (IFNβ1a) 22 mcg subcutaneous injection three times per week
Trial: 20308220
Drug: Prescription of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription of condoms
Trial: 18173156
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Tianmeng Capsule (Control)
Trial: 15804995
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ondansetron (5 mg/m2) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Trial: 15804995
Drug: Orally disintegrating
RxNorm normalized name: Clozapine Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally disintegrating tablet (ODT) ondansetron (4-8 mg according to body surface area) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Trial: 12020139
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (specific mobilization techniques)
Trial: 12020139
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (exercise therapy)
Trial: 12020139
Drug: Continued care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued care by a general practitioner (analgesics, counseling, and education)
Trial: 8551733
Drug: High-dose ACMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ACMF (6 cycles): 130 mg/m2 CPA, 26 mg/m2 MTX, 600 mg/m2 5-FU, 26 mg/m2 ADM
Trial: 8551733
Drug: Low-dose ACMF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ACMF (12 cycles): 65 mg/m2 CPA, 13 mg/m2 MTX, 300 mg/m2 5-FU, 13 mg/m2 ADM
Trial: 2112243
Drug: D‐penicillamine 10‐12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐penicillamine 10‐12 mg/day
Trial: 2112243
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate 50 mg intramuscularly weekly
Trial: 2112243
Drug: Pulse oral
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse oral methotrexate 7.5‐15.0 mg weekly
Trial: 2112243
Drug: Withdrawal rates
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal rates due to adverse drug reactions
Trial: 389419
Drug: Placebo normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo normal saline (S) infusion
Trial: 31434498
Drug: rt-PA treatment
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA treatment combined with fisetin
Trial: 22099425
Drug: Curcumin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1 g/d, n 46)
Trial: 19007835
Drug: MMRV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMRV vaccine (Priorix-Tetra)
Trial: 17967669
Drug: Rocuronium 50
RxNorm normalized name: rocuronium 50 mg/5 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 50 mg mixed with 8.4% NaHCO(3) 3 mL
Trial: 17967669
Drug: Rocuronium 50
RxNorm normalized name: rocuronium 50 mg/5 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 50 mg mixed with 0.9% NaCl 3 mL
Trial: 8903921
Drug: Tamoxifen (20‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20‐30 mg/day)
Trial: 2699011
Drug: Classical anaesthesia
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical anaesthesia with benzodiazepine‐analgesic (diazepam and fentanyl)
Trial: 30004255
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (SSRI) users
Trial: 10334388
Drug: Group III
RxNorm normalized name: Corticosteroids, potent (group III)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III (8 patients without hepatitis virus markers with Hb > 85 g/L)
Trial: 10334388
Drug: Group IV
RxNorm normalized name: Corticosteroids, very potent (group IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV (11 patients without hepatitis virus markers with Hb < 75 g/L)
Trial: 7492041
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy in the Gamow bag at 1.58 atmospheres absolute pressure (8.5 psi) for 40 minutes
Trial: 7492041
Drug: Normobaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normobaric oxygen through a nonrebreather mask at 15 L/minute for 40 minutes
Trial: 1827105
Drug: Clarithromycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (2 x 125 mg capsules, 12-hourly)
Trial: 1827105
Drug: Penicillin VK
RxNorm normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin VK (2 x 125 mg tablets, 6-hourly)
Trial: 28640385
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) consolidation therapy
Trial: 17302926
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene measures provided by dental hygienists once every 3 weeks (Group A)
Trial: 17302926
Drug: Nursing staff
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing staff provided daily oral hygiene after hands-on instructions (Group B)
Trial: 15145325
Drug: Twice-daily isophane
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily isophane insulin (Group 2)
Trial: 15145325
Drug: Basal/bolus isophane/lispro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal/bolus isophane/lispro insulin (Group 3)
Trial: 15145325
Drug: Continue tablets
RxNorm normalized name: morphine Extended Release Oral Tablet [MS Contin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue tablets (Group 1)